Sweden · Delayed Price · Currency is SEK SynAct Pharma AB Earnings Call Transcripts
Fiscal Year 2026
-
The phase II-B ADVANCE study showed that 40 mg resomelagon, combined with methotrexate, achieved strong ACR20 and ACR50 responses and significant reductions in inflammation markers in early RA patients, with a favorable safety profile and no immunosuppression. These results support phase III development and strategic partnering discussions.
-
The company is advancing a novel, non-immunosuppressive oral therapy for immune diseases, with phase II-B data in rheumatoid arthritis expected soon. Success could open broad market opportunities and lead to partnerships for phase III and commercialization.
-
Key clinical data from three programs are expected in the next two quarters, driving a shift to active business development. The lead RA program targets early, high-activity patients with a novel, non-immunosuppressive therapy, while host-directed therapies for respiratory infections address major unmet needs. Strong financials and a dual-track strategy support broad partnering opportunities.
Fiscal Year 2025
-
Resomelagon is advancing in phase IIB trials for rheumatoid arthritis and host-directed viral infection therapies, with major data readouts and a dengue study expected next year. The approach targets immune modulation, aiming to improve outcomes and reduce side effects.
-
Advancement of the RA Phase 2B study, new PMR and dengue programs, and robust patent and financial positions set the stage for major partnering opportunities. Funding is secured through 2026, with key clinical and business milestones expected in the next 12–18 months.
Fiscal Year 2024
-
A refocused strategy prioritizes the ADVANCE phase II study in newly diagnosed, high-activity RA patients, aiming for data by end of next year and subsequent partnering. Resomelagon offers a novel, immune-preserving approach with strong efficacy in the right subgroup, addressing a large unmet need in RA and attracting significant industry interest.